Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Surgical Science Sweden, Capital Markets Day, CMD, 2025

By Inderes12/8/2025, 1:00 PM
Surgical Science Sweden

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Anna Ahlberg
00:19 - 04:08

Hello everyone, and a warm welcome to Surgical Science Capital Markets Day 2025. My name is Anna Ahlberg and I am the CFO for Surgical Science. We have a hybrid event here today, meaning that we have both participants on-site as well as people listening in digitally. A warm welcome to you as well. The event will also be filmed and posted on our website after we have finished here today. It has been almost three years since we had our first Capital Markets Day at Surgical Science. On February 22nd, 2023, we look forward to being able to present the company and our plans in more depth to you here today. As we have communicated, we have been working on a new strategy for some time, and in order to capture all the possibilities we see in the market, this strategy is reflected in new financial targets for the company, which we announced in a press release earlier this morning. Our agenda today is as follows. First, we have a shorter chapter that we call 'Surgical Science Today,' where we discuss who we are, our purpose, mission, and current position. And after that, we will delve into our new strategy and strategic plan. Here we will talk about the market size and growth, and our place in it. We will also discuss our five key market segments. We will do a deep dive into each one of them, look at priorities per segment, and also discuss profitability per segment, to see what actions we can take to improve it. We will also touch upon acquisitions in this section. The strategy is reflected in our ambitions as well as our new financial goals, which we, as mentioned, sent out in a press release this morning and that we will get back to during this session. We plan to have a break at 3:15 for 15 minutes, and after this, we have a chapter that we call expanding the market, where we will delve more into our sales strategy. After expanding the market, we will have some concluding remarks and then a question and answer session. So we ask you to please hold any questions until the question and answer session. We will, of course, take questions from both the audience present here today and from those of you who are listening in. We who are here from the management team today are our CEO Tom Englund, our Chief Revenue Officer responsible for sales and services, Niclas M Olsson, and myself. We also have our chairman and former CEO in the audience, along with our board member and former chairman, Roland Bentsen. Once again, a warm welcome. We hope you will find the day interesting and rewarding. And with that, I would like to hand over to our CEO, Tom Englund.

Tom Englund
04:10 - 16:26

Thank you, Anna. Hi everyone. My name is Tom Englund. I'm very happy to host this first Capital Markets Day for me, as it has been some time since we last held our Capital Markets Day about three years ago. Furthermore, we've just concluded the work on our new strategy and have also presented our financial goals. And it's an opportune moment for us, of course, to tell this story and speak more about what we plan ahead. Before I start with our first session on Surgical Science today, I want to comment on the news that we sent out on November 25th regarding Intuitive cancelling the Memorandum of Understanding about simulation from Surgical Science on their DB5 robots. The news indicated that simulation software from Surgical Science would be optional and only shipped to a select group of DB5 customers. The most important customers that they, Intuitive, have for DB5, and this recent development is, of course, disappointing, both because we have announced a Memorandum of Understanding earlier, but also because it shows doubts about our customer relationship with Intuitive. At the same time, simulation for robotic surgery, as you will see here in a second, is more strategic than ever. We are working more closely than ever with Intuitive on the roadmap ahead. We intend to cover this entire strategic development in the robotics section of the presentation here. Further on, we will discuss what plans we have going forward for the segment. But before we get there, I want to start with a bit of background into Surgical Science today and our business today. That's Surgical Science. We have a very important purpose, our 'why,' that unites us and engages us tremendously. This purpose is new for us with the revised strategy and has been altered from our previous mission statement, with the main change being that we have expanded the market to encompass all healthcare professionals. Our purpose is to unlock the full potential of every medical professional to improve healthcare outcomes and save patients' lives. We believe that our business and target customers encompass all healthcare professionals globally. This is a customer group that numbers in the millions of professionals, where we have only scratched the surface and served a couple of thousand of them today. The impact of our products and services results in better healthcare outcomes for patients, ultimately saving patients' lives. This is an important purpose that the entire Surgical Science team stands behind, rallies behind, and is engaged by, along with our vision. We believe in a world where medical professionals should train and also get certified in a simulated environment. We believe that this industry should focus and function in the same way as the aviation industry, where pilots receive their certification in a simulator and also need to be recertified every year according to certain procedures and assessment criteria. Today, we are quite far from this vision, but we feel accelerated development towards it, and our activities in the strategy, as you will see. Aim to take us further towards this future. The value proposition for simulation is very strong, and it's growing due to trends in the healthcare market. With simulation, healthcare professionals can train in a safe and repeatable way to achieve the necessary skills before engaging in clinical procedures. Simulation exercises can vary in difficulty, and different patient parameters can be adjusted to create a variety of scenarios for the surgeon. These exercises can also be based on the proficiency of the surgeons and create a so-called proficiency-based learning journey. Simulation also allows for standardized and quantifiable results, eliminating the need for subjective assessments that were historically used, as well as the need for proctors or human supervisors with the introduction of more and more digital tools and advanced instrumentation. Simulation also becomes a powerful technology for training in the safe operation and enablement of these tools, both inside and outside the body. And finally, simulation is a scalable and sustainable technology, as opposed to the often-used wet lab infrastructure, where animals or even cadavers are used today. There is a clear movement away from these types of training environments, and more and more of them are being questioned. Simulation is the sustainable alternative. Several studies have also demonstrated the superiority of simulation in reducing training times compared to traditional techniques, as well as enhancing the procedural quality of surgeons. At our website, you can explore 400 different validation studies that provide evidence of the validity and reliability of our simulation technology, which has helped pave the way for revolutionizing surgical education and training. The evidence is overwhelming. Simulation is a very powerful technology to teach psychomotor skills, to increase the quality of surgical procedures, and to make surgeons and healthcare professionals more efficient. There is a range of different training tools for medical education today, spanning from simpler, traditional tools such as basic learning and training tools to more advanced ones like high fidelity simulation. High fidelity simulation, which is the area that Surgical Science focuses on, strikes the right balance between introductory and advanced motoric training, with a high level of realism and flexibility in the scenarios provided. Since it is a simulation, you can get repetitive training to build muscle memory to ensure that you attain the proper proficiency and procedural skills before operating clinically in the patient. Often, these tools and technologies are also used in combination, where students can start out with basic learning tools before moving on to, for example, simulation. As you can see to the right, cadaveric and animal training is still in use today, but as I said, it is increasingly being replaced by more sustainable methods such as high fidelity simulation. Apart from the obvious ethical concerns with this type of training, the cost is also very high and requires dedicated facilities such as wet lab infrastructure. Surgical Science today is the clear world leader in high fidelity surgical simulation, with a very talented team of around 320 people. Our installed base of around 10,000 simulators is bigger than that of any other company in our market. But at the same time, as you will see, it only represents a small fraction of the potential in the market. We have a broad and strong distributor network, which will increasingly become an asset for us as the company grows and expands into more business segments. A recent development since our last quarterly report is that we have consolidated our US operations into our Cleveland office, where we will create a so-called customer center. The aim is to provide even better support for our US customers from Cleveland, and therefore, as a consequence, we have decided to close our Seattle operations. However, our customer-facing capacity on the West Coast of the U.S. remains unchanged and will improve over time. During the last years, Surgical Science has grown both organically and through acquisitions. The acquisitions of Sense Graphics, Mimic, and Simbionix have all been very successful, enabling the company to add revenue, products, and customer relationships in a very synergistic manner. The most recent acquisition we made, Intelligent Ultrasound in January of this year, was executed on very favorable terms for Surgical Science. However, it has impacted the company's results during this year and is a significant reason for the lower profitability this year. However, we are very satisfied with the acquired assets of Intelligent Ultrasound, primarily within the product portfolio, which opens up new markets for us within ultrasound simulation. We have worked extensively internally to capture our unique competitive advantages, how we create customer value, and the reasons why our customers choose to work with us today. These insights are described in what we call the Surgical Science Advantage. Customers today choose Surgical Science for its high pace of innovation and world-leading products. These products provide unmatched value for our customers. Stay with us. In part due to the continuous high pace of innovation and value delivery by our team. We have an ambition to provide amazing customer experiences with a high degree of authenticity and clinical accuracy, and we want to make our customers advocates for us and medical simulation. The fact that we have a broad product portfolio and a large global support structure means that we can become a turnkey partner for our customers as well. For simulation, infrastructure, and operations. With services such as simulator fleet management solutions, we can ensure uptime and correct deployment of simulators across assets globally for our customers. The combination of these strengths will become even more important in a market where we will address a broader customer category, not just early adopters. The four strengths in combination are also what is necessary to enable our customers to move from operating single-unit simulators to the deployment of larger fleets of simulators internally and for the market, allowing it to increase further in size. One of our biggest prides internally is that we have some of the world's most prominent research institutions and hospitals, as well as medical device companies and robotic surgery companies as our customers. Our company was founded more than 25 years ago, and many of these companies have been with us for numerous years. This means that we have a high ratio of returning customers, which is truly exceptional. And many of these customers, especially in the med device space, are also very big, meaning that there is a future opportunity for continued growth for each customer. Having a customer roster like this also serves as a powerful reference as we progressively delve deeper into the market. We would like to conclude this chapter with a video highlighting one of our customers, Andrew Ear, Medical Director at the Stratus Center for Medical Simulation in Massachusetts, United States, as he explains the value of simulation and the Surgical Science advantage.

Andrew Ear
16:34 - 18:47

The Center for Medical Simulation is the simulation center for Brigham and Women's Hospital in Boston, Massachusetts. We focus on a wide variety of skills and courses. We focus extensively on non-technical skills. We work extensively with high-fidelity mannequins, but we also conduct a significant amount of procedural training, especially with our surgical colleagues. The landscape of medical education has significantly changed over recent decades. It used to be acceptable to learn on the patients, but in order to do it safely, there are now better ways to train and learn than we had many decades ago. Simulation has become a critical part of the training algorithm. It allows people to practice, train, and learn from mistakes in ways that don't harm patients or cause damage to themselves as providers. We used to expect and accept that some errors and mistakes would happen. That's really not acceptable anymore. And simulation has made it possible for us to elevate people to a level of competence. And so, using simulation, people can learn exactly what the techniques are and learn exactly how to approach a procedure. And so, it has really propelled the patient safety movement light years ahead. Our center is one of the oldest centers in the United States. We've been doing simulation for about 20 years, and we really pride ourselves on finding the right tools and the right technologies for what we're trying to do. And while there are lots of companies out there, Surgical Science has proven itself to be really at the forefront. The technologies are user-friendly. They have a wide variety of products that truly fit the types of skills and content that we're aiming to teach. Moreover, the service has been phenomenal when issues arise. If we have questions or concerns, or if we're looking to change our simulators, that team has consistently been there, demonstrating their support over a prolonged period and building a strong relationship with our center and staff.

Tom Englund
18:56 - 39:38

This concludes our first chapter, Surgical Science Today, and we will now move into our next chapter, Strategic Direction and Value Creation. In the Strategic Direction chapter, we will explain our financial goals, our view on the high-level market, and our targeted segment and strategic high-level goals. In the Value Creation section, we will delve deeper into each of the targeted segments, which in some ways can be seen as businesses within the business, and explain our goals and priorities for each of these segments. As you have seen from this morning's press release, we have issued new financial targets for Surgical Science. Revenue growth shall amount to 10 to 15% annually, with an adjusted EBIT of at least 15%. We estimate that these targets will be met in 2027 as a consequence of the previously communicated news about the company's customer, intuitive profitability, and some sales growth expected for 2026, although not in line with the targets. Furthermore, we intend to deepen our presence in our already existing market segments, which include minimally invasive surgery simulation, medical device simulation, and surgical robotics simulation. Furthermore, we aim to expand the ultrasound simulation segment into a significantly larger business than it currently is. We also have an ambition to grow our smallest segment, emergency medical simulation, from inception stage into a real business. The goal of this new strategy is to create an even more stable foundation for the company, with five distinct business segments and exposure to a significantly larger total market than before. We will leave these goals for now, and add significantly more details and plans, and then come back to the financial goals at the end of the presentation. Speaking about the market, Surgical Science operates in the healthcare education market. This is a huge market which represents everything from various programs within university education, different educational platform companies, platform technologies, educational technologies, learning management systems, and healthcare training by pharma companies. Et cetera. Et cetera, et cetera. Medical simulation. The red sliver. There is a subset of the educational technologies and content segment, which is represented by the beige color. Our internal estimates, supported by various market reports, show medical simulation to be a very, very small part of this very large market, approximately 2%. This is an illustrative picture to show that medical simulation still is a very small part of the overall healthcare market. The healthcare education market is set to grow at a fast pace in the coming years, driven by a few megatrends such as aging populations, increasing complexity of care, and workforce pressure. Medical simulation, then, is a very suitable technology and tool to address the consequences of these trends. If we then dive deeper into the global medical simulation market where Surgical Science operates, we estimate this market to be around 25 billion SEK in size. This market comprises of manikin-based simulations or patient simulators, screen and web-based simulations where you learn through a computer app or interface, physical or task trainers, or so-called anatomical models, and finally, immersive and device-integrated simulations, which is what we do. We assess that the market addressable to Surgical Science and our products and services is around 9 billion SEK. Here, there is an opportunity for us to both take market share in already existing segments. The red part in the left bar represents where we sell products today, but we also have opportunities to grow into other product categories, represented by the other colors in the graph. As you know, Surgical Science has two overarching business areas: educational products catering to training at hospitals, simulator centers, and universities; and the industry segment where we cater primarily to medical device and surgical robotics companies. We assess that educational products constitute the larger part of the addressable market today. Industry OEM constitutes a fifth to a third of the market, but with much faster growth than the educational market. Additionally, I would like to add an asterisk here to emphasize that market assumptions can be quite deceiving. In a relatively small market with low penetration, the market is shaped largely by the main players, and market sizes and growth rates will be highly dependent on the success of the individual companies and their initiatives. We will now move away from our market estimates and instead focus on the strategic direction of the company. We have decided to actively target five distinct market segments in our new strategy. As you know, we have historically reported on the division between educational products and industry OEM in our financial reporting. We believe that this traditional split is too broad and presents an overly general view of our target segments, and therefore, we have broken down the market further into five prioritized segments. Minimally Invasive Surgery simulation is our biggest segment today, representing around 30 to 35% of our sales. The ultrasound simulation segment has grown significantly due to the acquisition of Intelligent Ultrasound, and now represents 15-20% of our sales. The customer base is somewhat similar to that in minimally invasive surgery simulation, but we are also addressing much larger customer subsegments here with different product categories. Emergency Medical Simulation is our smallest segment, still largely in incubation mode. In this segment, we address customers in the emergency, first responder, and defense areas. And the large order that we announced earlier this year for a government agency in a Southeast Asian country belonged in this segment. Surgical robotics simulation is our second-largest segment. Here we act as a supplier and OEM partner to these robotics companies, and our solutions provide safe and efficient onboarding and proficiency. The development of surgeons on the robotic platforms of our customers. And finally, we have an exciting field of medical device simulations, where our customers are medical device companies who use simulation to provide safe and efficient onboarding for their customers, similar to robotics companies. But these device companies also use our solutions and simulators as tools for their sales and marketing teams to demonstrate the features and benefits of their products safely and efficiently. Looking at our business models, these vary depending on the segment. For ultrasound and EMS simulation, so one, two, and three, we develop and sell simulator hardware together with software modules for surgical robotics. We engage with our customers in development projects and then are paid licenses for every robot that ships with our simulation. For medical device simulation, we also first engage with our customer in development projects to build bespoke simulators for these companies, and then we sell them custom-developed simulators throughout these often very large organizations. Service and support are always an integral and integrated part of any offering. Our clear ambition, and this is very important, is to make each segment profitable on its own, and for these segments to contribute to the overall profitability of the group. Today, as you can see, robotics simulation has the highest relative profitability due to the licensing business model. There is limited relative profitability improvement potential from where we stand in this segment today, but all the other segments contribute to a far lower degree to the overall profitability. One big opportunity and major objective with this strategy is to increase the profitability in all other parts of the business. Aside from surgical robotics, there is significant upside and tangible improvement potential in these areas of the business. In order to reach our financial goals and eventually double the size of the company, as we have an internal ambition, we have defined six strategic objectives that will serve as our long-term goals for the coming years. Our first goal clearly states our ambition for continued growth by delivering world-leading products within our target segments. The second goal is to ensure that our customers become happy, satisfied users of our technology and simulations, enabling them to achieve their goals with proper onboarding infrastructure around the simulators and the necessary knowledge. Thirdly, we have an outspoken ambition to make simulation a standard practice within healthcare education, both as a training and, very importantly, as a certification tool. This will have a significant impact on how deeply we can penetrate the market. One goal is centered around the ability to launch new businesses from inception. Here, we are actively working to achieve product-market fit. Now, for the Emergency Medical Simulation segment, we foresee continued growth for our company. We foresee continued growth for our company. We want to ensure that we grow in a scalable and financially efficient way so that we can both expand while maintaining good profitability in line with our financial goals as we do so. And finally, we would not be able to achieve anything without our exceptional team, our exceptional people at Surgical Science. This objective focuses on how we are most efficient in our internal collaboration and processes, as well as how we develop our organization as the company grows. As I pointed out in the previous slide, one of our strategic objectives is to develop world-leading products with an ambition to create an amazing customer experience. As an example of an amazing customer experience, we would now like to introduce to you the Robotics Express, our latest addition to our product offering, which you can see here. Physically on the stage to the left of me, Robotics Express is a portable simulator that makes robotic surgery training more accessible, enabling healthcare professionals and trainees to build skills efficiently and affordably, without taking time away from the operating room. The simulator is compact and lightweight. As you can see, it has a small footprint, enabling training wherever your surgeons are, without the need for a dedicated facility. Previously, robotic surgery training could only take place on the robotics console, which then competed for time when the console was used for clinical work. We have now described our addressable market, our financial and strategic goals at the highest level. And we've also presented our five prioritized market segments. Now, in the value creation chapter, we will do a deep dive into each of these segments and the respective opportunities that we see in our plans for each segment in more detail. As a backdrop for the presentation of our value creation plan, first, some data points. Surgical Science shows a 14% growth year-to-date in the third quarter compared to the same period last year. We've had a revenue growth of around 11%. Since 2021, revenue growth in the industry has been significantly stronger than that of educational products. Our industry customers, which predominantly are medical device and surgical robotics companies, have shown more resilience in their spending during the economic downturn. On the other hand, hospitals and SIM centers, which are customers in our educational products segment, have seen significant cuts in their CapEx budgets, impacting our sales performance in this area. Our profitability, which has been around 20 to 25% in previous years, has decreased this year to around 10%. The main reasons for this negative development are a shift in revenue stream mix away from license revenues towards more hardware, the acquisition of Intelligent Ultrasound, which at the time of acquisition was an unprofitable company and still weighs on our results. And finally, unfavorable currency effects. As I've already pointed out, we have historically divided our business into two business areas: Educational Products and Industry. OEM and educational products comprise around 500 million, or half of the company's revenues. But as I've already mentioned, we have divided this segment further into three subsegments: Minimally Invasive Surgery, Ultrasound Simulation, and Emergency Medical Simulation. And we will now present them in more detail. Each of them. Our first segment, Minimally Invasive Surgery Simulation, is our biggest segment and comprises around 35% of our total revenues today. It covers solutions for surgeons and physicians to train in various kinds of procedures related to minimally invasive surgery. We have four main product categories in this segment: laparoscopy, endoscopy, endovascular, and robotics. Endovascular and robotics are the fastest-growing segments. Product segments. Whereas endoscopy remains flat and laparoscopy is decreasing in sales, minimally invasive surgery techniques have been growing in importance for many years now. For many years now, minimally invasive surgery techniques have grown in importance and are often favored over traditional open surgery. We also see an acceleration towards minimally invasive surgery away from open surgery. Clearly, there is a significant shift happening in the field. This development has in turn driven the need for simulation in order to teach minimally invasive surgery in an efficient way. However, there is still a large skills gap and a massive training need for surgeons and healthcare professionals in this field. This training need is growing as the shift towards minimally invasive surgery (MIS) is increasing, with an estimated 1.2 to 1.5 million specialty surgeons globally today. Only a minority have received formal EMIs training. The value of the technology is also evident, as more and more hospitals and residency programs increasingly require their students to go through simulation classes before performing MIS procedures clinically, which further drives simulation adoption. Adoption within the segment. Now moving over to ultrasound simulation. Our ultrasound simulation business has increased in importance with the acquisition of UK-based Intelligent Ultrasound, and it now constitutes around 20% of the company's revenues. Ultrasound and ultrasound simulation are image-based technologies, which is a different tech stack than what we use for, for example, minimally invasive surgery simulation. The customer base includes both hospitals and simulation centers, but it also extends much broader than that, including nursing schools, sonography programs at health schools, emergency departments, and so on. At the beginning of the year, we concluded the acquisition of Intelligent Ultrasound. However, we have not been satisfied with the financial performance and sales growth of the ultrasound simulation product category over the past year. As such, the acquisition has weighed heavily on the group's profitability. However, with the acquisition of Intelligent Ultrasound, we have become the clear world leader in ultrasound simulation in terms of sales, with a significantly broader product offering than before. We can now use this combined product offering to sell to existing customers as well as address completely new segments and customer groups that we couldn't reach before. Point of care ultrasound, or POCUS, is an application where ultrasound is used at the bedside by physicians as an early diagnostic tool, and this area is growing rapidly. Hospitals and training programs are increasingly mandating Pocus competencies for residents and nurses. We also see that training needs extend beyond traditional user groups such as doctors to include nurses, first responders, and medical students. They all represent fast-growing cohorts. For us, surgeons are now increasingly expected to use ultrasound for new applications, such as guidance procedures in nerve blocks, ablations, and different types of biopsies, and not just as a diagnostic tool anymore. Finally, we see a strong and increased focus on women's health generally, and there is a rising demand for early pregnancy assessment. Infertility diagnostics and maternal fetal monitoring. All these factors are driving the demand for ultrasound training and ultrasound simulation tools. We have high ambitions internally for this segment, and we believe that we can see considerable growth in the years to come. However, we are simultaneously realistic that further work is required in creating awareness for new target groups, as well as in developing our product offerings to capture some new use cases and customer groups. We will now look at the video where a few of our key opinion leaders speak about the value and strong rise of point-of-care ultrasound and the importance of proper POCUS simulation.

Video
39:39 - 39:51

Point of care ultrasound is changing how care is delivered. By bringing imaging directly to the bedside, clinicians can make faster, more accurate decisions in critical moments.

Video
39:54 - 40:31

Clinical ultrasound is probably the one medical advancement that has brought the provider back to the patient's bedside. It's a dynamic process making these critical decisions, especially for the more ill patients, and you're trying to get them ready. Essentially, when the training wheels come off and they're not with an expert user, how are they going to be able to identify the pathology? How do you integrate all the things that you're learning? And then more importantly, how do you make good medical decisions? And if you're having to do that all in real-time with an unstable or critically ill patient, cognitively you might make a lot of mistakes.

Video
40:33 - 40:55

Using POCUS effectively requires more than just access. It demands skill, confidence, and practice. High-quality simulation helps build the skills to use POCUS without the pressure, offering hands-on practice and realistic, risk-free environments where mistakes become learning moments and skills turn into second nature.

Video
40:56 - 41:26

It's low-stakes training. With the simulator, you don't have to worry about pushing too hard. You don't have to worry about feeling silly because you've never touched a probe before. And then the beautiful complement that simulators offer with pathologies that you would never see anywhere else. A big part of what we do is providing yes or no binary answers. Is there an effusion or is there a pneumothorax? How are you going to recognize a pneumothorax if you've never seen one? Well, that's the beauty of simulation.

Video
41:27 - 41:37

Pocus empowers clinicians. Simulation prepares them. They're improving patient care. One scan, one decision, one learner at a time.

Video
41:38 - 41:54

We have to believe that we've trained them well, that they're really smart already, and that they'll be able to use the ultrasound training we provided to them by using a high-fidelity simulator. That's really intuitive and easy to use. We can fast-track that learning significantly.

Video
41:55 - 42:00

Get in touch with our experts in healthcare simulation and kickstart your POCUS learning program today.

Tom Englund
42:05 - 52:51

The next segment, and the smallest one still in incubation mode, is Emergency Medical Simulation. Here, we focus on the development and sales of simulation training solutions to provide defense medical professionals and first responders with the necessary skills and knowledge to manage medical emergency situations. We kick-started this segment and the ambition in this area with a large order to the Defense Ministry in a Southeast Asian country, and our ambition is to continue to grow with sales towards customers in the defense sector. Additionally, we aim to adapt the product by creating a version for civilian use as well. This version will be sold to first responders, emergency staff, and other blue light personnel, which represents a different customer category than that for, for example, MIS. Our products here consist of mixed reality and virtual reality solutions, where you manipulate mannequins and tools physically with your hands while being in a virtual environment of your choice. For example, at the site of a car accident or in an emergency room of a hospital. These solutions provide a high level of immersiveness and realism, and they are very flexible in that they offer easily adaptable scenarios with quantifiable and immediate performance metrics and results. We consider the opportunity within this segment to be very significant for Surgical Science. Within defense, spending is rising rapidly as EU member states have increased defense budgets by 17%, reaching a record €279 billion, and these are expected to grow by an additional €80 billion per year by 2027, according to Goldman Sachs. We are already active in this space, as I mentioned before, with a major deployment for a Southeast Asian defense customer, and we also have additional defense and national readiness projects currently in the pipeline. On the civilian side, only in the US, there are over 250,000 employed emergency medical technicians and paramedics, and estimates suggest a total of over a million licensed or certified EMS personnel. Underscoring the potential for training, recertification, and upskilling, this creates a recurring sustainable demand for high-quality training solutions, including initial, refresher, and advanced skills with scenario-based simulations. One reason we see particularly strong interest in our mixed and virtual reality solutions is that defense and emergency organizations increasingly require training formats to reduce their reliance on proctors and supervisors. These formats offer repeatability and provide immersive, scenario-driven environments, which are ideal conditions for VR-based digital simulation platforms. We will now have a look at a video showcasing one of our products, Emerge X VR, within emergency medical simulation. This product is designed to teach specific emergency procedures in a VR environment, which provides a high cognitive load for the trainee and a very realistic training scenario. Now we'll turn our attention to our industry segment. This segment comprises the other half of Surgical Science's revenues, and it's been growing by around 20% during the past years. The industry is made up of two subsegments: robotic simulations and medical device simulations. And we will now describe the segments and the opportunities for us in more detail, starting with robotics simulation. The robotic simulation segment constitutes our second-largest segment, with around 30% of total sales from development projects and licenses. Depending on how you define it, the market ranges from anywhere from 100 to even 400 different companies. However, if you only consider soft tissue robotics and look at the major players, there are about 20 to 30 companies. Robotic surgery is at an inflection point, with even stronger projected procedural growth than currently seen, driven by the value advantage over open surgery, the value advantage over general minimally invasive surgery, and increased competition. It is very clear that robots will be a key part of the infrastructure in the operating room and hospitals of the future when all these robots come to market. There is a massive training need for surgeons to accelerate product adoption and, of course, for the new robotic companies to market their respective products. Proof of this need is that only around 100,000 out of the 1.2 million specialty surgeons, or 1 in 10, have been trained on robotic surgery, whether it be on a Da Vinci system or any other manufacturer. Furthermore, the digital innovation of the robotics companies will pick up speed as the pace of hardware innovation decreases, and this is a natural progression that has happened in many different markets outside of robotics. Robotics companies see that digital innovation represents an opportunity for differentiation and continuous value delivery, while also enabling the possibility for large recurring revenue streams. Simulation plays a crucial role in the learning journey for robotic surgeons. A generic learning pathway, as you can see here on the slide, typically consists of several steps with more basic system introduction and early training, followed by advanced training and procedural support. Simulation is crucial for the surgeon in the early stages when learning the ropes of a new robotic system and building the necessary muscle memory. Simulation is also used later in the learning journey, as the surgeon learns specific procedural steps where the quality and efficiency of these steps are paramount. Historically, these later parts of the training journey have also been carried out with cadavers or animals, and these methods, once again for sustainability reasons, are now being replaced by simulation and anatomical models. Many robotic companies, if not all, are running initiatives to reduce the dependence on cadavers or animals in their training. Historically, simulation has been used by robotic surgeons in the early phases of training, with a focus on teaching the introductory motor skills of the surgeon. This is what we referred to on the previous slide as system introduction and qualification. However, the trend is now shifting towards more advanced simulation and also towards supporting surgeons much later in their training journey. The surgical robot can be seen as a sensing unit, which collects large amounts of data from its instruments and from the scene camera, much in the same way as an autonomous vehicle collects a lot of data from its surrounding environment. This data can then be used to produce insights for surgeons on their clinical efficiency and areas for improvement. Improvement areas. All major robotic manufacturers today have these types of capabilities within their digital offerings. Intuitive refers to it as Case Insights. Medtronic calls it Touch Surgery. These insights can then be used to recommend different areas for improvement and simulations that the surgeon should focus on, and the surgeon can then train on these areas in a simulated environment repeatedly until the performance is improved and the surgeon can return to the operating room. In the future, simulations will be adapted to the proficiency level of the surgeon, incorporating increased difficulties or changing environments. Specific patient characteristics and emergency situations that might occur mean that even very experienced surgeons will find training value from the simulation. This means that simulation will become part of a continuous learning journey throughout the careers of surgeons. And this is what we mean when we. For example, in the press release that we sent out, we say that simulation will become an integrated part of the digital ecosystem of the robotic surgery companies. We would now like to listen to our Chief R&D Officer, Ariel Benmosche, as he explains the future developments in robotic simulation and the use of AI in our development efforts.

Ariel Ben Mosce
53:07 - 54:19

Advanced AI technologies are something that we are actively pursuing and developing in Surgical Science R&D to make personalized recommendations for surgical training a reality. We are using huge datasets and training advanced models that will offer personalized recommendations for follow-up training after each simulation session. Imagine that these technologies could also connect to performance data from real surgeries in actual time, allowing for the closure of the training loop between the real and the simulated. Advanced AI technologies are something that we are constantly using in the R&D for Surgical Science. It helps us code better, be more efficient, design a huge variety of anatomies for our simulated cases, and allows us to bring advanced user experiences like interactive voice recognition supporting multiple languages to our products.

Tom Englund
54:23 - 67:17

I want to add that the use of AI in our development work will benefit not only robotics simulation, of course, but all the different product areas that we have. This picture represents a list of the most important robotic surgery customers globally, and all of them are customers of Surgical Science. In terms of market share of the installed base, Intuitive still dominates the market, with more than 10,000 systems installed. It has taken considerably longer for the challengers in the market to come out with their robots than was previously estimated, and this has also affected the license revenues that we predicted for Surgical Science when we established our financial goals in 2022. We initially anticipated the figures would be significantly higher than they are today. However, many robotic companies are now actively selling their products on the market. Among Surgical Science customers here, it's only Johnson & Johnson with their Ottava platform that are not yet selling their robots in any part of the world. And the focus now for these companies is, of course, to get their robots approved for more procedures and also to globalize their sales efforts. The latest news that we have here is that Medtronic, one of the largest medical device companies on the planet with a huge project to bring out the Hugo robot, last week got their FDA clearance for general sales in the US for urologic surgical procedures. This is a major step for the company, and it will significantly increase Medtronic's robot volumes. It is important to note that Intuitive will maintain a very high market share of the installed base in the coming year, both due to their already large installed base and their market success with existing products, most notably the latest release, Da Vinci Five. And this concludes the robotic simulation chapter. Now I would like to move over to the Med Device Simulation chapter segment. Our customers in this segment represent some of the largest medical device companies in the world. These companies use simulation both as a means to train their customers in the safe operation and installation of their medical devices and as a sales and marketing tool at events and customer meetings to showcase the features and value of their products. Simulation is predominantly the primary method that medical device companies use to demonstrate their equipment without physically placing it into a patient, and as such, simulation has become a crucial training and revenue-generating tool for these companies. There are several trends pointing towards the increased use of our technology here. Medical devices are becoming more complex, requiring simulation-based onboarding for safe adoption. These steeper learning curves for the more complex devices drive demand for faster and more efficient training. Med device companies are also launching numerous new and sophisticated products more than ever before. And finally, there is a trend towards sustainability, moving away from using animals and cadavers. Similarly, much like in the robotic space. Most of our companies here today are within the endovascular or cardiovascular field, and therefore you can see our endovascular products, such as Angio FlexPro and Angio Mentor Suite, are in the highest demand for this segment. Our customers in the med device segment represent some of the most important med device companies globally, and we have long-standing relationships with many of them. Many of them have been our customers for years and use simulation as an integral tool in their marketing and educational efforts, devoting significant internal resources to operating their simulation infrastructure. The power of the customer base is also evident in our sales results for this segment. Sales within medical device simulation have grown steadily over the past years, and you can see how the development revenues, represented by the light blue bar, are a driver for increasing simulator sales. The dark blue bar represents the simulator sales in the years thereafter. One example of this is the large order, potentially the largest single deal in the company's history, that we announced with our quarter three report just recently for one of the world's biggest device companies. This development project is currently underway and will be fully completed in 2026. After that, we will equip the customer with the simulators we have developed for them, and we believe that this revenue stream will continue for at least four years. Following that period. The number of development projects that we undertake for our customers is also a very clear leading indicator for ensuing simulator sales, which is a testament to our long-term relationships. Sorry. As you can see, these projects have grown steadily in the past few years, and we have a high degree of repeat customers, which is a testament to our long-term relationships and the customer success that we create. And finally, to emphasize the importance that simulation has for these companies. We see a very strong potential to keep growing this segment, given that the trends in the market are so favorable for simulation and for Surgical Science. The product launch pace in this field is very high, particularly in the cardiovascular segment depicted in this graph. There are around 12 new device launches or devices that receive FDA approval in the US every year. These devices are introduced almost every month in various types, becoming more intricate in their operation and installation, which significantly heightens the need for surgeons to receive comprehensive training. At the same time, as you can see on the bars, there is a rapid growth in the number of patients who actually receive these devices as well, depicting the sales of, in this case, cardiovascular devices. Several large med device companies show significant growth numbers in this area, which in turn means that the number of surgeons needing training to install them is also increasing. So this concludes our deep dive into our five different market segments. We have described the segments and our market opportunity in more detail. And now what we have done is define a set of strategic priorities for each segment within our strategy, which we are currently executing on for MIS and ultrasound. The priorities are to increase our profitability, drive market penetration, and delve deeper into the existing market segments. We also have plans to launch amazing new products designed to provide more value for our customers and to capture a wider set of customer personas for emergency medical simulation. We intend for the segment to prove itself as a viable business, and to bring the product offering from the defense side to the civilian market. For robotics and medical devices, we aim to continue with our successful key account strategy, providing our distinguished customers with superior value. Specifically, for robotics simulation, our goal is to close this loop, embark on this learning journey, and integrate simulation as a core component of the digital ecosystem within the continuous learning loop. The financial goals that we communicated today are based on organic growth, with no acquisitions factored in. However, we are continuously considering acquisition opportunities that can contribute with either customer base, product diversification, synergistic products, market access, or strategic intent. Sorry, strategic talent. This is the same perspective and plan that we have had on inorganic growth previously with the older strategy, and it remains unchanged. Then, with the new strategy, I would like to end this chapter. Strategic direction and value creation by speaking a bit about our profitability improvement efforts, since this is an important part of our strategy and the financial goals. And since we feel today that it's only the robotics segment that has an acceptable profitability level. We are currently conducting a variety of activities to improve our gross margins. We're making various changes to our product portfolio to drive volume and improve the product mix. We are also actively working on price increases and price management with various activities to increase our average sales price, or ASP. In parallel, we conduct another set of activities to reduce our cost of goods sold or the production cost of our products. As we noted in our latest quarterly report, we have started seeing positive effects already from this work. Although the results are somewhat hidden due to the negative currency effects that we have had at the same time. But we believe that this positive impact will further increase in the coming quarters. We are also working very actively to improve our organizational efficiency and ability to do more work and create more output with the same or fewer people. One of the initiatives that will have the biggest impact is to unite our software and hardware development around a set of platforms on the hardware side. These platforms will enable us to configure base designs, which will be important both for reducing our production costs and for significantly increasing our volumes. On the software side, a consolidation of our software platforms will enable faster development times with more reuse of existing software assets. This, in turn, will also enhance our ability to manage more simultaneous customer projects and provide faster response times for our customers. In parallel to these platform initiatives, we're also working across the organization with various projects to improve our overall organizational efficiency. These range from general digitization efforts aimed at making the entire team more efficient so we can increase our agility and scale sales and the number of customers while maintaining or only slightly increasing our staffing. And then finally, we have another set of activities specifically aimed at improving our sales efficiency, and Niclas M Olsson will elaborate on this. Here, our Chief Revenue Officer will explain more about this after the break. To conclude, profitability improvements in the parts of the business outside of robotics are a key part of the strategy. In this last part of the chapter, we have provided more details on how these profitability improvements will be achieved.

Anna Ahlberg
67:25 - 68:07

Welcome back. We will now move on to the next item on the agenda. Expanding the market will be presented by our Chief Revenue Officer, Niclas M Olsson. We operate in an under-penetrated market with generally low awareness of medical simulation, which indicates great potential for us as a company. A key to how much and how fast we can grow in the coming years is related to how we can develop and build strong and efficient sales channels. Therefore, we are heavily focused on this aspect in our strategy. And I welcome Niclas to present this in more detail.

Niclas M Olsson
68:13 - 85:41

Thank you very much. I'm a bit of a wild card here because I'm a typical sales guy. I will try to curb my enthusiasm and show you the facts. I've been instructed not to move across this line or that line and to stand still. So I will do my best here. We are in a very interesting situation now where we have built, I would say, by far the most superior sales and sales channel network in the industry. We have, I would say, five regions including the Americas. We are separating the USA from the rest of America. Given the significant impact we have solely from our business in the US, we are also focusing on EMEA. We consider the UK as a direct market, and we have isolated APAC and China for the same reason due to the impact and success in China. We are servicing the Americas and the US market from our Cleveland office. And as Tom mentioned, we are now building a customer interaction center in Cleveland to be able to work closer to our customers, while servicing EMEA from Gothenburg. And we have a sales office now in Cardiff as well in the UK. From Tel Aviv, we are servicing APAC and from Shenzhen, the China market. We are also expanding our services out of the Shenzhen office, and in the future, we will see how much more we can cover of the APAC market. We have a fantastic sales and service organization. We are actively recruiting from our competitors. We are by far the most attractive employer in our industry. We have a lot of people joining us from the customer side, especially when it comes to the industry business. Today we have approximately over 90 distributors scattered around the world and in significant markets. We have, I would say, 2 to 3 partners to be able to balance and to utilize our strategy. In a better and more aggressive way. What is really going to change for us when it comes to sales and service is technology. I hope that you had a chance to play with the Robotics Express here. It is a game changer. And why is it a game changer? Well, first and foremost, because it's a customer-driven project. Originally, we had a discussion with Karolinska here in Stockholm, and they said that it's so difficult to get console time for their surgeons. We have to stay long hours to train on the system. Couldn't you build something that the surgeons can bring home so they can practice after putting their kids to bed and having their dinner? So that's how these projects started, and this has turned out to be a success. How do you say in English, a hit, a product with very great, huge interest from this project? And now, as we combine an ultra-portable product with AI features, including learning management tools, we are building in insights. It means that the surgeon can learn what they are doing wrong. And when we are selling this product, we try to compare it to a golf simulator. If you have a simulator that only tells you how far you're hitting a stroke, but you never get feedback, What can I do better? How can I improve? How can I become better? And what is really interesting with our products and our technology, if we look at it from a historical perspective, is that we have taken beginners to proficiency. But then what? The market that we have addressed is approximately 160,000 beginners a year. That is what is being produced. Surgeons being produced each year. But by implementing learning tools, individual measurements, and guidance and proctoring, as we say in the healthcare space, we are expanding the market to, I would say, approximately 1.6 million professionals. And what evidence do we have of that? Well, one of the first customers of this simulator is a US surgeon who called us up and ordered one sight unseen. And the listing price for this simulator is approximately $65,000 in the US. And this is what people are willing to pay for in a product that they can use as a personalized tool. As we say, how do we make the best ones even better? And that's why we talk about how our strategy is significantly expanding the market. Looking then into sales and service, how will we accelerate the growth? How will we drive growth from where we are today? Well, as mentioned before, we have sales and channel development. In our distributor network, we are running numerous efficiency programs in sales, implementing new IT tools and AI-supported tools for managing quotes and business operations. An equally important part here is to drive simulation as an integral aspect of medical training. How do we achieve this? As Tom said before, an integrated part of the healthcare system, you can't fly a plane without ever recertification. You can't fly a plane without recertification, but you can perform surgery 20 or 30 years after graduating from medical school without any recertification. And we see a huge interest today from medical institutions, university colleges, etc. Provide us with tools so we can certify our surgeons and our staff in general. No other organization has a product with the same reach as we do. When we launch a new product today, we can utilize our sales channels to rapidly distribute them in the market. And here's a bit of a success story. The first Latin American customer of the Robotics Express was a Peruvian hospital, and it was a big surprise to all of us that we could reach Peru in just a few weeks after launching a new product. So speaking about market penetration, we conducted quite an interesting study on this topic. We are by far the biggest company in simulation. But how much have we penetrated the market? I think these figures are quite stunning: in the US, where we are performing very well, we estimate the number of prospects to be approximately 6,000 customers. And for anyone who is into the details, we know that there are far more hospitals in the US. And if you then add ambulatory surgical clinics, colleges, and universities, the figure is far higher. However, the way we calculate it is that these are the ones that are relevant to us and our business. And still, we only have, I would say, 10% penetration of the market for various reasons. If we then go to a region like APAC, we have approximately 16,000 relevant prospects in APAC. India has approximately 50,000 hospitals. So, we are being very conservative here. And when we are now launching products with lower price points to build scale, we know that we need to focus significantly on the under-penetrated markets going forward. From a global perspective, we currently hold 5% of what we believe should be our market share, even with a conservative approach. There are now many initiatives in the world when it comes to medical training. One of the reasons is that many surgeons today are reaching the later stages of their careers. And how do you educate people on new technology without the use of technology, as that is a bottleneck today. For example, in Mexico, it's just been announced that they will be building approximately 1000 CIM centers across the country. We don't think that we will sell 1000 simulators, but it will certainly drive interest and opportunities for us. And we have already seen an uptake in Latin America now this year. Coming then into the area of how do we manage, how do we work with all these distributors and all these channel partners? We are launching a concept that we call the partner path. The partner path means that we need to offer a variety of services. If you are a small channel partner with us in Colombia, you can't expect the same service level as you would in China if you are a major channel partner there. So the partner path concept means that we are setting up different service models depending on the potential and performance. Whether you fly first class, business class, or economy with us depends on your potential performance and how much you co-invest to support the partner path. We are now launching something that we are very excited about. It's the partner portal. We are digitizing our sales efforts here so partners can log on. They can use our tools to come up with the right configuration for products. They can do the quoting, they can place their orders, etc. On the partner portal. And this will give us a completely new way of scaling the business. Instead of educating everyone in the various meetings, we conduct campaigns, digital campaigns, and explore Edu initiatives. I would say that it presents different challenges compared to industry education. Customers buy less frequently than industrial customers. Our channel partners need to have access to the right information to successfully close a deal. With this tool, we can scale. We can work with electronic orders. We can provide faster support. On our side, we have real-time visibility into what is really going on in the market. And we can direct resources based on market activity. based on the activity in the market. We can also ensure that what's being sold complies with our business practices. And we are, of course, regularly onboarding new distributors as we grow into new markets. The industry is potentially even more interesting. The challenge in working with the industry is that we are undertaking a major project with one of the top three companies in the United States. They sometimes spend millions of dollars developing a technology with us. But how do they create awareness among their subsidiary companies worldwide that this technology is now available? And what is really interesting is that this program is endorsed by major companies. Help us to make it visible what we can buy from Surgical Science. Every time I visit a new market, I receive the same feedback from the big medical device companies asking why they are not informed about what is available to them. Because the med device companies use our technology predominantly to train and educate their customers, but also to sell their products and, in some cases, to conduct R&D work. So if I work in an R&D department of a large medtech company, how can I be aware of what's being done on another side of my company? We are working very closely with the big companies to set up what we call private rooms, where we put all the available assets for them in one secured area where they can provide us data and we can provide them products. When it comes to really driving credibility and adoption, working with medical affairs is crucial for us to collaborate with leading institutions. Credibility and adoption are very important to us, and working with medical affairs helps us collaborate with leading institutions. We have ongoing projects with Cedars-Sinai Hospital in Los Angeles, the Cleveland Clinic in Cleveland, and Rigshospitalet in Copenhagen. This is how we build the trust for that. Our technology represents reality. And with this credibility, we can turn our products into commercially successful platforms. There are many. I wouldn't say alternatives, but today with different digital tool sets. We have all seen what's going on now with AI-generated content. It's still extremely important to have scientifically based products, and that's why we are working very closely with medical affairs. There are a number of associations around the world and we are working with, I would say most of them, and the associations are the ones that set the standard for a specific discipline. Even when working with an association, it strengthens our credibility and enhances their opinion of us. Leaders can, of course, then hopefully speak in our favor. One of the latest agreements we have is with ESG, the European Society for Gynecologic Endoscopy. They have training programs for robotic surgeons, and they are present in 156 countries. To be accredited by this association, you must complete a skills test using a robotics mentor from Surgical Science and our software. Why is this important? Because when we look at the number of new robotic entrants, there will be more players on the market deciding which platform to use to certify a surgeon. And we see a trend now that more and more are turning to agnostic solutions like Surgical Science. So here is where we see a great opportunity going forward, having our own platforms. That opens up opportunities for surgeons to practice in their homes and at the hospital without taking productive time away from the consoles in the hospitals. To sum it up, to wrap it up, I would say that we are in a very favorable place for scaling up our business with the new technology. We strongly believe that this AI-enabled technology will take us from being proficient to becoming the best you can be. It's a game changer for us in our industry; instead of treating everyone in this room as a single group, we will focus on each individual and design specific programs to help you become the best surgeon possible. And we already see evidence today that this is generating a lot of interest from the market, and we are very excited about our potential. So that was pretty much everything from me. Thank you.

Tom Englund
85:46 - 89:34

Thank you. Niclas M Olsson. As we approach the end of our presentation, we have reached the concluding remarks. And as a short recap, this strategy that we have presented today defines our five key market segments: minimally invasive surgery simulation, ultrasound simulation, emergency medical simulation, robotic simulation, and medical device simulation. These five market segments represent a significantly larger addressable market than outlined in previous plans. The strategy also involves significant profitability improvements in all segments except for robotics simulation. For each of our market segments, we have defined a set of strategic priorities aimed at creating customer and market success, as well as contributing to our financial goals. Then we have started to work on projects to drive growth and improve our profitability, and these initiatives will have a continued positive impact in the quarters and years to come. And finally, Nicholas has, in his chapter, explained how we intend to expand the market through a set of specific activities aimed at increasing simulation penetration and driving simulation adoption. We have today also updated our financial targets. The revenue growth of 10 to 15% will, in the coming years, come from growth in both existing and new segments, and the strategy implies that the company will target a significantly larger market and more revenue streams than previously. We aim for at least 15% adjusted EBIT. As we start delivering according to these goals and the strategic plan, our ambition is to continuously increase our financial targets. And today, we have also announced that the company will start working on transferring its listing from the First North Growth Market to the Nasdaq Main Market in Stockholm, and we will initiate this work at the beginning of next year. The main reason we're doing this is that we believe we belong on the main market. We have been listed on First North since 2017, and we feel that we meet the governance standards of the main market and are ready as a company. We also believe that the main market listing will open the Surgical Science shares to many more investors. Certain investors have rules that prevent them from investing in companies outside of the main market, and this means that Surgical Science will now open up for them. And finally, being on the main market improves our capital management flexibility with more tools such as, for example, repurchasing our own shares. And this, ladies and gentlemen, concludes our presentation for today. Thank you for listening. Thank you for listening to our story. We will continue to advance Surgical Science and create value for our customers and shareholders through innovative strategies and technologies. I can tell you that our team is extremely excited, highly engaged, and looking forward to the journey ahead. And with that, we would like to open up for Q&A.

Anna Ahlberg
90:06 - 90:46

So we now move on to our question and answer session. If you are in the audience and have a question, please raise your hand and wait until you have been handed a microphone. And once you have it, kindly state your name and organization and then ask your question. If you are joining us online, please feel free to submit your questions in the chat box below the video, and we would appreciate it if you ask one question at a time. Ulrich.

Ulrik Trattner, DNB Carnegie
90:47 - 91:30

Thank you very much. And thanks, Tom, Anna, and Ulrich from DNB Carnegie. I guess I'll address the million dollar question. The focus of your procedure-specific simulation in the news flow is on Intuitive choosing to insource or in-house develop basic skill simulation. How confident are you, especially given the presentation you recently provided here, that software is becoming a more integrated part? What hinders Intuitive from developing procedure-specific simulation in-house?

Tom Englund
91:32 - 94:14

Thank you. Great question. So if you remember the slide I showed with the different steps in the learning journey of the surgeon in the robotic simulation chapter, you have the early steps, which involve more basic simulation leading up to the later steps. So the further steps include the more advanced procedural type of simulation, the ones that we now provide with Surgical Science towards Intuitive. We believe that basic simulation tools can be developed using engines like Unity or Unreal, which are similar to the computer graphics used in video game development by other companies. Whereas the more advanced procedural type of simulation requires real-time physics engines and a considerably more advanced and complicated tech stack. We believe that there is a significant trend in the continuous learning journey, where surgeons will increasingly practice in more advanced scenarios over time. There is a very strong case to be made that procedural simulation will become a very important part of that entire digital offering. And then, of course, your question is okay, so if you can do it, can somebody else do it? Here, I would say that there are a couple of different answers. Firstly, it has taken the company many years to reach the position we are in today. And we have quite a talented team. So, I think we have a strong head start. It's considerably more difficult to build this type of procedural simulation than the more basic skills. And then thirdly, it might not necessarily be in the interest of the respective robotics companies to do this type of simulation by themselves, because it goes back to what Niclas said about the generic trainers and the training driven by the societies rather than the robotics companies, and creating credible certified standards that you can certify surgeons against. And that should be done then with neutral bodies rather than the manufacturers themselves. Our plan here is, of course, to lean in and maintain a high pace of innovation to ensure that we remain a proactive supplier for the robotics companies. At the same time, we're working together with the medical associations to develop these standards and certification processes, as well as innovating and developing our own tools, such as the Robotics Express that we have shown.

Ulrik Trattner, DNB Carnegie
94:16 - 94:32

And just a follow-up. What is the reasonable penetration rate of procedure-specific simulation? Before the announcement, I believe Intuitive stated that they had approximately 40% penetration of their installed base, but that also included basic training.

Tom Englund
94:33 - 95:00

And that is difficult to tell because it depends not only on the value of these different technologies, but also on how Intuitive plans to sell it, to which customer cohorts, and so on. They plan to sell it. That's why we will not comment on a specific procedural or specific attach rate, but rather we have provided a fairly large range regarding the financial impact that this news has for our company.

Ulrik Trattner, DNB Carnegie
95:01 - 95:15

And if I can squeeze in one. Also, as a follow-up, did you get any sense or any heads-up that Intuitive was developing a basic skills simulation for the DB5? Given that you were part of the development of the DB5.

Tom Englund
95:15 - 96:01

We work very closely with Intuitive. We have done so for years, and we have an intimate relationship with their development teams. We have never disclosed or had any discussions about these types of changes from a commercial standpoint. But of course, we have some insight into what they're generally working on. But no, it was a surprise for us. The change in the MOU was, of course, a big disappointment for us. That hurts us in the short term. But as I think, I hope that you also feel now that in the long term, it can actually have a lesser impact. Given that we see procedural simulation playing such an important role in the digital ecosystem among these players.

Ulrik Trattner, DNB Carnegie
96:02 - 96:03

Thank you.

Tom Englund
96:09 - 96:09

I think.

Anna Ahlberg
96:11 - 96:12

Oh, okay.

Ulrik Trattner, DNB Carnegie
96:12 - 96:13

So I can continue.

Anna Ahlberg
96:14 - 96:15

We had one in the front.

Ulrik Trattner, DNB Carnegie
96:15 - 96:49

Thank you. Everyone else in the room. Robotics Express. Obviously, I understand what you're planning to do here, taking it into a generic segment, trying to open up the minds and the skills of resident surgeons and those not getting the ability to sit down in a DaVinci, for instance. But the software itself looks very similar to what Intuitive is offering, built into their DB5 system now with the basic skills. So what customer segment are you planning to address here?

Tom Englund
96:50 - 98:29

The customer segment that we're planning to address with the Robotics Express includes the broad beginner base, as Niclas had in his triangle there, his pyramid, as well as a certain set of other professionals. And what you need to do is to offer a comprehensive simulation offering that covers the entire learning pathway. And then, of course, in the beginning, when you're learning the ropes of a robotic system and you start to understand how to handle the clutch or the instruments, there is limited differentiation you can achieve in terms of exercises, and it's about actually making the simulation fit the specific robotic modules. So what we have not shown here, for example, is that this generic trainer can also be equipped with different types of grippers and different types of clutches to fit the different robotic models. So in that sense, it's going to be more of a specific experience. It can be a more specific robotic experience for one specific manufacturer. So in that sense, it's flexible. And as you delve deeper into procedural simulation, there is a wide variety of procedures and critical steps that you can simulate. And there, I think it will differ from manufacturer to manufacturer, sorry, from robotic company to robotic company. And also, we will continuously develop that part. So there's a lot of room and opportunity for continuous value delivery when you get into the more advanced procedural content.

Ulrik Trattner, DNB Carnegie
98:30 - 98:52

I experimented with it. I got the understanding that it doesn't include haptic feedback. And I guess if you're a new surgeon trying to apply robotic surgery, haptic feedback is indeed one of the most important skills to develop in order to get started with robotic surgery. So how much of a problem is it that it lacks haptic feedback?

Tom Englund
98:53 - 99:46

So, of course, we have done a lot of customer interviews before conceptualizing the product. One of the discussions is around the need for haptic feedback, and there are only a few platforms that offer it. Or, if we consider it, very few robotic platforms have haptic feedback today, and most of them do not. And you can also effectively learn the introductions without haptic feedback. And it also has to do with striking this balance between accessibility, portability, and, let's say, more realism or more proximity to the actual robotic simulator. So in that case, if you want to practice haptic feedback, you can do that on a procedural simulation from Surgical Science, such as a console, instead. So those are the types of balances we always have to strike in product development as we develop our products.

Simon Larsen, Danske Bank
99:49 - 100:07

Great. Great. Simon Larsen from Danske Bank. I was just curious because you mentioned wanting to improve the product mix as you move forward. So what does this really entail? Is it more software content or more standardized hardware, and is it about bringing gross margins higher or what exactly? Yeah, what does this involve?

Tom Englund
100:07 - 101:07

It's a range of different factors. It's a good question. It's a range of different activities. And we sort of touched on them in different parts of the presentation. One is this platform thinking, both on the hardware and software sides. Right. That allows us to have fewer product variants with a few base models on which we can base a lot of different products. And the same applies to software, having a few platforms that you can build from using reusable software assets, which will also help margins. Then it can also involve what we call product-related decisions. So, for example, we are a company that should focus on high-volume production rather than what we call 'Swiss watch manufacturing,' where only a few simulators are produced annually for a specific product. And that means reshaping the product portfolio to actually target higher volume products and, of course, also the higher volume segments. So those are some of the initiatives that we're undertaking.

Simon Larsen, Danske Bank
101:08 - 101:27

Yes, perfect. And also, I guess the new financial targets are set at 10 to 15% for the group. Is it fair to assume then that we will have higher growth coming from the medical device OEM side and a bit lower from the education sector? Or how do we achieve the 10 to 15% as we progress?

Tom Englund
101:28 - 102:20

I mean, please feel free, but the 10 to 15% is if you look at the momentum right now, the momentum is much stronger for industry than for educational products. We have mentioned that the educational products can also achieve a double-digit growth year, but this has been greatly hampered by the budget situation and shortages in hospitals. So again, here we have adopted the principle of caution. Principle of caution and we said that the average is around 10 to 15. We believe it's crucial to begin achieving these targets so that we can progressively increase them as we move forward. But you're right that we definitely foresee the industry, medical devices, and also robotics achieving a significantly higher growth rate once the new robots are introduced.

Simon Larsen, Danske Bank
102:21 - 102:37

Maybe a final question if I can fit that in. I think you mentioned the big med device contract that you won in Q3; it will last for four years as it rolls out in terms of products. Is that a typical timeline or product life cycle for that type of product?

Tom Englund
102:37 - 102:39

What do you say about that?

Niclas M Olsson
102:40 - 102:50

I mean, I would say that when it comes to medical device simulation, first and foremost, we have the development phase and then we have the rollout phase. But then we also have the maintenance and support phase.

Tom Englund
102:51 - 102:51

So that we can see.

Niclas M Olsson
102:51 - 103:28

You can see, you can hear me. Oh, you can see, you can hear me. We have three phases: develop, build, and deliver. And then we have maintenance and support. So it actually continues. And this is a very sizable project. So normally, the design and build phase may last about two years. This one is significantly longer. But we see a trend that more and more of these projects are emerging due to the shift from using human cadavers and animals. So there is a trend today in the industry to move away from that space and into the digital space. Did I answer your question?

Simon Larsen, Danske Bank
103:29 - 103:37

Yes, I believe so. I think so, yeah, maybe then to conclude, a four-year lifecycle or rollout is perhaps a bit on the longer side compared to others.

Niclas M Olsson
103:38 - 103:39

The size of the project, of course.

Simon Larsen, Danske Bank
103:39 - 103:40

Yes. Makes sense.

Tom Englund
103:40 - 104:28

What will also happen is that some projects will involve certain medical device products. What happens is that they have some sort of mid-life upgrade or enhancement. After a few years, they develop improvements and then approach us to make enhancements. A new development project and then the hardware simulator can perhaps remain for another couple of years. So that extends the number of years from four to perhaps five or six. And then it also gives us an opportunity to sell new software modules onto those simulators as well. And I think it's a fantastic situation that we're in with these kinds of med device companies, because as the pace of innovation is so high, as I showed, there's ample room for growth within each of them. Right. It's more about our internal capacity to handle these projects at times. That actually limits how many projects we can undertake.

Simon Larsen, Danske Bank
104:30 - 104:31

Very clear. Thanks so much.

Anna Ahlberg
104:31 - 104:34

I think maybe we have a question over here.

Eric Foster, Private Investor
104:37 - 104:57

Hi. Eric Foster, private investor, in a new computer company, which is fortunate. So I'm a happy investor. AI is the new element in the room. What potentials or risks do you see with AI? Do you see? Would it be easy to use AI to replicate what you have accomplished over a number of years here?

Tom Englund
104:58 - 106:44

Yeah. So, as Ariel spoke about in his video, we use AI in our product development to build better products. And Niclas spoke a little bit about what type of features and functionalities you can get from AI. You can gain more insights from the actual output of the simulator, allowing the AI or software to better guide you through your proficiency journey or learning journey. Right. And then we also use AI, of course, as many other companies do, as an internal efficiency tool in all the work that we do, both in R&D and other areas. And then your question about whether AI could replace the procedural simulation that we're doing today by taking a dataset or even clinical imagery and then creating simulation out of that? We still think that is quite far away, given that the foundational models needed to do so have to be very, very big. And there's a significant effort going into that. And you also then have to do a simulation that is not just approximately 60 or 70% accurate. It needs to be clinically accurate and valid, right? That's what we discussed as one of the key aspects of our Surgical Science advantage. So, in order to get to that level, we believe we are still quite far away. But of course, as a leader in this space, this is something that we are monitoring very closely and actually trying to take advantage of and build on because we know this space better than many other companies or much of the ecosystem. So that's how we think about it. We're actually trying to utilize this as much as we can and maintain a strong base of innovation.

Eric Foster, Private Investor
106:44 - 106:45

Thank you.

Anna Ahlberg
106:46 - 106:47

In the back.

Ulrik Trattner, DNB Carnegie
106:54 - 107:21

Thank you. Here again from DNB Carnegie. A question on educational products. My impression. And based on the history of Surgical Science, the profitability of the educational segment is largely volume-driven. It's volume dependent. We had a discussion a year ago where you stated that you observed improvement in the procurement and tender activity within the industry. What's the state of the industry right now?

Tom Englund
107:23 - 109:09

Regarding your statement about it being volume dependent, I have some thoughts. I'm not sure I agree, actually, with all due respect, I think that we have opportunities to become more efficient in our production, but definitely also in our sourcing activities with the initiatives that we're doing on the platform side. There are many profitability improvements that we can implement on our production costs in general for educational products. But then, of course, as you say, with increasing volumes, we can distribute the work over more units if we are efficient. So that will definitely help. Then your second question, I believe, was more about the overall state of the business for educational products. And here, I believe, we see a mixed picture. I would say certain markets are growing very strongly as we recorded 45 or 46% growth in EMEA last quarter, for example, while other markets, such as our important US market, show more sluggish development. And here, what we are trying to do is, of course, to have specific plans for each and every one of these markets. But of course, we cannot expect the same kind of growth rates right now from where the US is today, considering the type of development they have compared to EMEA. One of the things that has really worked well, even in economic difficulties, if I look back at my experience, is that if you launch new products, even if it's a sluggish budget situation or sluggish economy, there can be a very high new product uptake, even in tough markets. That's why we strongly believe in launching new products as a vehicle to drive sales, both in markets that are doing well and in those that are not doing as well.

Ulrik Trattner, DNB Carnegie
109:10 - 109:27

And what about forward integration? It looked like your acquisition of Intelligent Ultrasound was somewhat of a portfolio acquisition, but it also involved acquiring a market presence in the UK. Are there more markets that you're open to taking over from distributors? What's your take on it?

Tom Englund
109:28 - 110:27

No, I think that on the industry side we have a very clear key account direct strategy and we will keep that because it's fewer customers, fewer accounts, and they require quite a high professional relationship with many different counterparts of the circle of Surgical Science interacting with the customer. We strongly believe in the distributed model for education because it's a model through which we can achieve extensive coverage, as Niclas mentioned, with more than 90 distributors globally. And we can also use this model as we have five different market segments, allowing us to create separate subdivisions or sub-segments of distributors, depending on the different segments that we target, because the customer groups are quite different. So, we definitely want to continue working with the distributor model. We believe that with some of the efficiency methods or projects we are implementing, we will become quite profitable in doing so as well.

Unknown
110:30 - 110:46

So you mentioned you want to scale on software. Historically, you kept the physics engine separate after the acquisitions and kind of had the final stage of integration in the software. Is that changing? So, you want to scale more. Could you please provide some additional details on that?

Tom Englund
110:46 - 111:52

So due to the acquisitions you mentioned, we have incorporated different tech stacks on both the software side and the hardware side into the company. And then there has been some integration done, as you pointed out, but not to the fullest extent possible. And I think one of the key parts of this plan now, as you can see on the OPEX slide there with the platform, is to consolidate the number of physics engines even further. The main reason for that is to be able to handle more customer projects concurrently and utilize more of the software assets we possess. And also, that entire team is trained on one specific engine, ensuring that all different improvements and work are pooled together, benefiting all of our customers. So it's definitely the ambition. This work has been ongoing for the last, I would say, 9 to 12 months. It has accelerated now with the new strategy to definitely reduce the number of engines. And that is also one of the reasons why we will be able to maintain an even higher pace of innovation moving forward.

Unknown
111:52 - 112:00

And along with that, there is a focus on five different areas. Is that like a reorganization starting today, or is it something you've already initiated?

Tom Englund
112:00 - 113:06

No, we are quite happy with the organization that we have right now. We haven't spoken about that specifically here, but we have a functional organization with a head of each of the departments. So we have the finance department, the sales department, the R&D department, the product marketing department, and so on. For a company of our size, with around 300 to 350 people as we are today, we feel that this is an adequate and most efficient organization. And then, of course, as you grow, especially on the business segment side, you could over time see that these five segments we have noted become more divisions or business areas within the company. But it's very, very critical that you do that at the right timing so that you don't introduce a lot of inefficiencies organizationally, but rather do it when the time is right. And we don't think that the time is right for now. So now we have a great organization. I think that the main challenge for us now is to manage these cross-functional projects across these functions that we have. We place significant emphasis on that aspect, and we believe we are managing it quite effectively.

Victor Westman, Red Eye Capital
113:08 - 113:43

Thank you. Victor Westman from Red Eye Capital was happy to see the decision to change the listing to the Nasdaq Main Market. And then I was equally disappointed when you told us that the reason for changing the listing was just for the sake of it. I would have thought that maybe share buybacks would be a no-brainer at today's valuation. So my question would be what would it take for stock buybacks to be the top priority on the agenda?

Anna Ahlberg
113:45 - 114:00

It was on the list. So it's definitely there. And once again, it's a tool that we would like to have. And then, of course, you need the AGM's approval. And it's a board decision. But it's definitely a tool that we would like to have.

Tom Englund
114:05 - 114:07

Should we take a question from the audience?

Anna Ahlberg
114:07 - 114:29

Yes. Let me see. Maybe a bit in line with your questions, but still, in which market segment do you see the highest growth potential and which segment do you expect to be the primary driver in achieving the overall growth target for the company?

Tom Englund
114:30 - 115:39

I think that the smallest market segments are, of course, the ones where we will have the highest growth rate just because of the simple mechanics of it. Right. So emergency medical simulation and also ultrasound. We're starting from very low levels there. But then I think that when it comes to the segments that will have the highest impact in reaching our overall sales growth target, it will definitely be minimally invasive surgery simulation, medical device simulation, and robotic simulation because they are the biggest ones and in both robotics and medical devices, we have a stronger growth rate. And I do think that if we are successful with the strategy of expanding the market, there is a very big upside also in minimally invasive surgery simulation, just because we still have a very low penetration in this segment. But I think the proof is in the pudding here, and it will take some time before we can see this kind of revenue growth accelerate to a different level than it is today. And on top of that, we have some macroeconomic factors that we need to take into consideration.

Anna Ahlberg
115:40 - 115:57

Then we have a question. Should we expect a scenario in which hospitals decide to only go with one RAS provider, meaning robotic surgery provider, given the complexity of training on several different robot simulations?

Tom Englund
115:57 - 116:48

I can start there and perhaps you can chime in. Niclas. But what we see in the market is that there is a clear need for alternatives to the incumbent robotic surgery supplier and that hospital management and surgeons welcome the newcomers. This is not only because it provides more competition and better price points, but we definitely think that the OR of the future will have several different robotics platforms. Perhaps in some cases, there will even be three different robotics suppliers, and the third one will be for specific applications that the two general robotics suppliers cannot handle. So we believe that is what's going to happen. Nicholas, do you want to comment further on that or?

Niclas M Olsson
116:48 - 117:49

I mean, in the markets where there's public tendering, hospitals can't choose. And we see that across Europe and in some other regions as well. And when you look into the current alternatives and the options that will come, there's going to be a drive for having multiple platforms. I just want to take the opportunity while standing up here to respond to the question about fidelity or haptic feedback. It's actually on the market and a non-issue because the robotic platform suppliers don't want the training device to be too similar to the real thing, so to speak. So it causes a problem with muscle memory, as trainees might believe they can operate the real equipment, so to speak. So we have a number of projects with the industry using this platform where we will configure it with, as Tom said, new grips, etc. But fidelity or haptic feedback has never been an issue.

Tom Englund
117:53 - 117:54

Great.

Anna Ahlberg
117:54 - 117:55

Thanks.

Ulrik Trattner, DNB Carnegie
117:57 - 118:27

Yes. Here again, we have a ton of moving parts here. There are two operating segments, yet a large number of products. You talk about improved profitability for educational products coming from different angles or sources. Wouldn't it make sense for you to be more transparent and start reporting a contribution margin per segment, enabling us to track the development going forward?

Tom Englund
118:27 - 119:38

Yes, you're absolutely right that this is the first time we have actively started discussing the different profitability levels, specifically the relative profitability levels, of our various segments. We haven't done that before. Right. In one of the earlier slides that we had here in the presentation. And we think that it's important right now to highlight these areas where we have profitability improvements. But then, of course, as these grow, I spoke about divisions and larger business units as this company grows. Then, of course, we will also start tracking these financially. However, it doesn't make sense, given the small P&L we have today, and the number of shared resources we have across these segments, to do it. And then, of course, internally, yes, we will monitor this and ensure that we maintain this ambition. As I mentioned, we work towards the ambition of having each of the segments profitable and contributing to the overall profitability. And then at some point, I don't know, we will probably open up and divulge a bit more, but rest assured that this is an internal, very, very strong focus.

Anna Ahlberg
119:40 - 119:43

Definitely, we will add more details as we go.

Tom Englund
119:44 - 120:11

And to your point, I also think it's important to illustrate the complexity and highlight the different parts of our business by delving deeper into and explaining the different segments, since it actually comprises five different businesses within the company, as you can understand, instead of attempting to obscure it at a higher level. This way, it's possible for you to understand the company, even with many moving parts, allowing you to conduct your own analysis more effectively. Not being transparent.

Erik Sprinchorn, TIN Fonder
120:14 - 121:00

Shifting focus to the smallest business area, which is emergency services. I guess just to get a feel for the ultimate risk scenario, right, is that you have this fantastic order which you complete and, you know, with success or not. But then there's nothing more because we don't know. We haven't seen it. And the upside is, of course, that every rescuer in the world has to perform some kind of training like this. So, what is it? Since you bring it up as a business segment, is it even feasible that this would just fizzle out and become nothing? Or, you know, what's your feel?

Tom Englund
121:01 - 122:46

It's a very good point. And as we said, it's less than 5% of the company's turnover. So it represents a very, very small part. Right. And as we were also very clear about, we started this when we received this order from the Southeast Asian company. And then we set this strategic goal as an objective to develop new businesses, because we believe that our technology is applicable and valuable in broader segments than just this one. But to your point, it is a different discipline to bring up small businesses rather than to work on improving existing businesses. Right. So you have to do it right. Both. You have to set the expectations. Right. And we have been very clear that this is an incubation, and we need to take it to the next step. In terms of financial forecasts, we have not allotted much revenue upside internally when revising these targets into that segment. Then it's about ensuring you have a dedicated team, allowing them to work independently, ensuring you reach product-market fit, and making the customer extremely satisfied. But of course, at the same time, it's important to maintain a strategic perspective of the market. And as you could see, it was very, very big, right? And it starts with one happy customer, a returning customer who comes back and perhaps even recommends it to another department within the same country, and so on. So that's how it starts. As I mentioned, we already have a substantial pipeline of similar customers. So, we feel pretty positive about this. But we are also very careful not to turn this into too big of a thing. But we think it's important for you to understand that this is one of the areas that could have very big potential going forward, while also speaking transparently about the time it will take until this becomes significant. Does that answer your question?

Erik Sprinchorn, TIN Fonder
122:46 - 122:57

Yes, it warms my heart since I'm one of the few people who've actually tried out the product before it was launched and critically failed at doing so.

Tom Englund
122:57 - 123:30

Yes, yes. In order for us to get into the bigger part of the pyramid and go deeper in the market, you can't launch half-mature products; you have to really nail it in all the different aspects. It becomes more like a consumer product. For example, this looks like an Xbox. It should behave like an Xbox when I open it. Same with this one. So we're definitely aware of the ambition level that we have to have internally to reach these markets.

Anna Ahlberg
123:33 - 123:57

Okay. Let's take one more question from the people joining us online. How far along are your customers today in adopting continuous learning workflows? Are you seeing tangible commercial demand for continuous learning modules today, or is this primarily a forward-looking opportunity you are investing in ahead of time?

Tom Englund
123:59 - 125:44

Our customers today are adopting continuous learning workflows in the sense that certain associations and societies are asking their surgeons to certify on a specific procedure. In that case, you could say that they have to do this continuously, but there are still very few associations and societies doing it in that way. And in many cases, our customers are hindered by the fact that what's available to them is limited to the software modules that we provide. There is no infrastructure or process in place. That's why it's so important to focus on medical affairs, work more closely with these associations and societies to develop continuous learning workflows, and also significantly enhance our LMS and cloud solutions so we can offer a comprehensive learning journey ourselves. Right. And that is something that is a big focus for us. So you don't do this kind of one-time training, but rather revisit the simulator and the LMS repeatedly. And the utopia or the dream is, of course, realized when you merge these two together, and our learning journeys coincide with the mandated certification processes of the societies and associations. So, you can actually learn and perhaps also obtain accreditation and certification with the LMS of Surgical Science. So I think you're pointing to one of the most strategic topics that we have internally in the company, which we are both pushing and taking a lot of action on. Thank you.

Anna Ahlberg
125:46 - 126:08

Thank you. And with that, I think we will conclude our Capital Markets Day 2025. Thank you to the team behind the scenes, all of you who joined us here today and those of you who followed us online. We truly appreciate your commitment. Thank you and goodbye.

Tom Englund
126:09 - 126:09

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…